Key result
Pretreatment of diabetic endothelial colony-forming cells with globular adiponectin significantly enhanced in vitro proliferation and in vivo neovascularization compared with untreated cells.
Why the study?
Does globular adiponectin pretreatment improve the functional capacity and neovascularization potential of endothelial colony-forming cells from diabetic patients?
Does globular adiponectin pretreatment improve the functional capacity and neovascularization potential of endothelial colony-forming cells from diabetic patients?
Preconditioning endothelial progenitor cells with globular adiponectin counteracts their functional impairment in a diabetic environment, enhancing neovascularization.
Answers are grounded in this paper and cite their sources.
No immediate clinical use for adiponectin-pretreated diabetic EPCs; hypothesis-generating for enhanced neovascularization in preclinical models.
OBJECTIVE: It has been shown that vascular progenitors from patients with diabetes are dysfunctional. However, therapeutic strategies to counteract their reduced functional capacity are still lacking. Because adiponectin has reported salutary effects on endothelial function, we investigated the functional effects of globular adiponectin (gAcrp), the active domain of adiponectin, on isolated endothelial colony-forming cells (ECFC). RESEARCH DESIGN AND METHODS: ECFC were isolated from peripheral blood of type 2 diabetic patients (dmECFC) and compared with ECFC of healthy young volunteers (yECFC) and nondiabetic age-matched control subjects (hECFC). Cells were treated with gAcrp for 48 h followed by assessment of cell counts, cell cycle analysis, and migration capacity. For in vivo evaluation, human ECFC were injected into normoglycemic or streptozotocin-induced hyperglycemic nu/nu mice after hind limb ischemia. RESULTS: Whereas dmECFC were functionally impaired compared with yECFC and hECFC, gAcrp significantly enhanced their in vitro proliferation and migratory activity. In vitro effects were significantly stronger in hECFC compared with dmECFC and were mediated through the cyclooxygenase-2 pathway. Most important, however, we observed a profound and sustained increase of the in vivo neovascularization in mice receiving gAcrp-pretreated dmECFC compared with untreated dmECFC under both normoglycemic and hyperglycemic conditions. CONCLUSIONS: Pretreatment of ECFC with gAcrp enhanced the functional capacity of ECFC in vitro and in vivo in normoglycemic and hyperglycemic environments. Therefore, preconditioning of dmECFC with gAcrp may be a novel approach to counteract their functional impairment in diabetes.
No takes yet. Share an insight, caveat, or question.
Leicht et al. (2011) studied Type 2 diabetes. Globular adiponectin (gAcrp) vs. Untreated cells was evaluated on In vitro proliferation, migratory activity, and in vivo neovascularization. Pretreatment of diabetic endothelial colony-forming cells with globular adiponectin significantly enhanced in vitro proliferation and in vivo neovascularization compared with untreated cells.
Synapse has enriched 10 related papers. Consider them for comparative context: